AMADIS
28.3.2022 07:02:12 CEST | Business Wire | Press release
PayPlug (part of the Payment activities of Groupe BPCE ) selects Amadis , a global payment software editor, to deploy its nexo based payment acceptance application, on an array of traditional payment terminals and Android SoftPOS devices, through a standardized payment acceptance approach, independent of EMV® Level 2 card processing frameworks. This drastically reduces deployment times, maintenance costs, and provides PayPlug with ownership over its card acceptance solutions. The alliance builds on the long-standing partnership between Amadis and PayPlug.
PayPlug’s new application enables every store associate to bring the check out experience to the customer, the POI (point of interaction), wherever the consumer needs it to be, by enabling Android NFC COTS (Commercial-Off-The-Shelf) devices, such as smartphones, tablets or professional dedicated instruments.
“Amadis provided us with an effective way to offer our SME customers with innovative, new ways to accept card-present payments,” said Antoine Grimaud, PayPlug CEO. “We expect the solution to drive new revenue opportunities for our customers, while generating new points of payment acceptance in multiple countries, and enhancing the customer experience.
PayPlug’s new application includes all components of Amadis One (Amadis’ SoftPOS solution), in particular OLA (Open Level 2 API). OLA is an abstraction layer that allows an enterprise to run a payment application with the EMV Level 2 stack of any terminal manufacturer or SoftPOS - allowing enterprises to be fully payment device agnostic, independent of ecosystem, hardware and operating system.
“The new PayPlug application represents a new era for payments acceptance, and we are excited to be a part of their solution,” said Emmanuel Haydont, Amadis CEO. “With nexo protocols a reality for customers, Amadis simplifies nexo deployments and reduces costs, while helping enterprises accelerate deployments and access to multiple countries.”
“We are delighted to see PayPlug, and its customers, become the latest company that will benefit from our standardization work,” explains Jacques Soussana, nexo standards Secretary-General. “Our specifications and protocols remove the barriers traditionally present in the payment acceptance ecosystem, including within non-traditional environments such as mobile acceptance platforms like smartphones, tablets and COTS.”
To make the solution more interoperable, PayPlug’s application needed to effectively integrate with nexo payment standards. Amadis simplified implementation with its open, standards-based off-the-shelf framework that is nexo compliant.
About PayPlug
PayPlug is the French omnichannel pay-by-card solution for SMEs. Since 2012, it has been offering an innovative and easy to use alternative to traditional market players: among other things, the fintech relies on its unique ecosystem of partners and integrated features to simplify all things related to payments for its 15,000 customers, retailers and e-merchants in Europe. After acquiring the status of Payment Institution approved by the ACPR Banque de France, PayPlug joined the BPCE group in April 2017. Over the last three years, PayPlug has experienced nearly 100% growth per year. www.payplug.com
About nexo standards
nexo standards is the association dedicated to removing the barriers present in today’s fragmented global payment acceptance ecosystem. It enables fast, borderless and global payments acceptance by standardizing the exchange of data between all payment acceptance stakeholders. The nexo specifications and messaging protocols adhere to ISO 20022 standards, are universally applicable and fully open. www.nexo-standards.org/
About Amadis
Amadis is a leader in compliant payment software technology, with its software running on more than 40 million devices worldwide. The company provides state-of-the-art software editing and development solutions for global merchants, payment device manufacturers and service providers. Amadis provides merchants with the industry’s broadest range of payment acceptance software technology options based on the most efficient available standards, independent of hardware, retail vertical segment, or geography. The company brings an elite, experienced software team to the industry and enables solutions for international fintech, processors and merchants in over 23 countries. Learn more at www.amadis.ca .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220327005013/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Provides Progress Update Regarding RelabotulinumtoxinA Regulatory Submission in the United States1.7.2026 07:00:00 CEST | Press release
Galderma received a Complete Response Letter from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization Relfydess is approved in 33 markets and already launched in more than 20, including across Europe, the Middle East and Australia, with an encouraging early launch trajectory supported by positive healthcare professional feedback Regulatory filings in other territories are ongoing and remain on track Ad hoc announcement pursuant to Art. 53 LR Galderma (SIX: GALD) today provided progress updates regarding the regulatory review of its pending Biologics License Application (“BLA”) for RelabotulinumtoxinA with the U.S. Food and Drug Administration (“FDA”). The Company has received a Complete Response Letter (CRL) from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization. As part of its review, the FDA conducted a Pre-License Inspection (PLI) of Galderma’s manufa
EVE Energy Showcases All-Scenario Energy Storage Solutions at The Smarter E Europe 20261.7.2026 03:45:00 CEST | Press release
EVE Energy unveiled its Mr. Big Family series, a 6.9+ MWh energy storage system, and all-scenario energy storage solutions at Intersolar Europe in Munich. Drawing on traceable large-cell technology, proven large-scale energy storage project delivery experience, and global delivery capabilities, the company is addressing Europe's diverse energy storage requirements across utility-scale, commercial & industrial (C&I ), and data center segments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630889717/en/ EVE Energy showcases its Mr. Giant 3.0 6.9+ MWh energy storage system at The Smarter E Europe 2026 in Munich, Germany Advancing Large-Cell Technology with Global Project Validation As one of the first companies to focus on large-capacity energy storage cells, EVE Energy has iteratively upgraded its cell platform from 560 Ah and 628 Ah to 702 Ah, adhering to a stacking process route throughout. At the exhibition, the Mr. Gia
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom